Shanghai Hile Bio-Technology Co., Ltd. (SHA:603718)
China · Delayed Price · Currency is CNY 2.900
-0.030 (-1.02%)
Aug 4, 2026, 3:00 PM CST
SHA:603718 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,891 | 4,000 | 4,546 | 7,046 | 6,324 | 9,853 | |
Market Cap Growth | -62.31% | -12.02% | -35.48% | 11.42% | -35.82% | 21.33% |
Enterprise Value | 1,643 | 3,711 | 4,343 | 6,992 | 6,101 | 9,857 |
Last Close Price | 2.90 | 6.10 | 6.84 | 10.55 | 9.61 | 14.98 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 26.56 | 112.07 | 52.00 | 182.95 |
Forward PE | - | 81.19 | 81.19 | 81.19 | 81.19 | 81.19 |
PS Ratio | 10.90 | 21.29 | 16.77 | 29.27 | 21.08 | 28.37 |
PB Ratio | 2.02 | 4.46 | 2.67 | 6.00 | 5.69 | 9.98 |
P/TBV Ratio | 4.79 | 8.90 | 9.11 | 7.39 | 7.51 | 14.46 |
P/FCF Ratio | 31.96 | 85.71 | 119.37 | - | 23.16 | 1683.00 |
P/OCF Ratio | 27.76 | 67.98 | 97.82 | - | 21.59 | 225.82 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 9.47 | 19.75 | 16.02 | 29.05 | 20.34 | 28.38 |
EV/EBITDA Ratio | 33.79 | 63.77 | 81.44 | 239.78 | 107.30 | 125.10 |
EV/EBIT Ratio | 45.31 | 82.38 | 234.40 | - | 388.87 | 450.14 |
EV/FCF Ratio | 27.78 | 79.53 | 114.03 | - | 22.34 | 1683.62 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.10 | 0.02 | 0.01 | 0.23 | 0.14 | 0.48 |
Debt / EBITDA Ratio | 1.87 | 0.27 | 0.31 | 8.16 | 2.51 | 6.01 |
Debt / FCF Ratio | 1.54 | 0.36 | 0.46 | - | 0.58 | 81.59 |
Net Debt / Equity Ratio | -0.32 | -0.46 | -0.29 | -0.07 | -0.21 | -0.06 |
Net Debt / EBITDA Ratio | -6.74 | -7.02 | -9.37 | -2.82 | -4.13 | -0.77 |
Net Debt / FCF Ratio | -5.02 | -8.75 | -13.12 | 5.08 | -0.86 | -10.41 |
Asset Turnover | 0.11 | 0.13 | 0.16 | 0.15 | 0.18 | 0.19 |
Inventory Turnover | 0.84 | 0.91 | 1.40 | 0.97 | 0.87 | 1.23 |
Quick Ratio | 3.68 | 4.75 | 6.27 | 1.06 | 1.55 | 0.99 |
Current Ratio | 4.27 | 5.34 | 6.90 | 1.35 | 2.07 | 1.46 |
Return on Equity (ROE) | -22.69% | -22.48% | 12.62% | 4.38% | 10.55% | 4.69% |
Return on Assets (ROA) | 1.47% | 1.91% | 0.66% | -0.26% | 0.58% | 0.75% |
Return on Invested Capital (ROIC) | 6.44% | 5.33% | 1.41% | -0.59% | 1.47% | 1.91% |
Return on Capital Employed (ROCE) | 3.30% | 4.40% | 1.10% | -0.50% | 1.30% | 1.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -16.72% | -7.79% | 3.77% | 0.89% | 1.92% | 0.55% |
FCF Yield | 3.13% | 1.17% | 0.84% | -0.23% | 4.32% | 0.06% |
Dividend Yield | 2.70% | - | 1.15% | 0.27% | 0.59% | - |
Payout Ratio | - | - | 12.60% | 60.28% | 0.56% | 5.54% |
Buyback Yield / Dilution | 4.38% | 1.45% | -4.72% | 1.77% | 4.93% | 24.58% |
Total Shareholder Return | 7.08% | 1.45% | -3.57% | 2.04% | 5.52% | 24.58% |